- Takeda's plaque psoriasis pill beats Bristol Myers' Sotyktu in Phase 3Takeda’s $4 billion bet on an oral plaque psoriasis drug has paid off again, as the company reported the pill beat Bristol Myers Squibb’s Sotyktu in a head-to-head Phase 3 study. Zasocitinib induce…Endpoints · 1mo ago↗ source
- Neion Bio raises $23M Series A to make proteins from chicken eggsNeion Bio has secured an oversubscribed $23 million Series A to further develop its technology that uses chicken eggs to make active pharmaceutical ingredients for biologic drugs. The funding round…Endpoints · 1mo ago↗ source
- Takeda’s $4B TYK2 drug tops Bristol Myers’ Sotyktu in head-to-head testThe results support Takeda’s long-held belief in zasocitinib’s superiority and could help it gain a commercial advantage over Bristol’s therapy.